Regulatory Requirement for the Quality Improvement Plan for a Stabilized Product Development

Nandini Ramani^*, Y. Sai Phanendra, G. Sirisha, Doonaboyina Ragava, Kavala Nageswara Rao
Department of Pharmaceutical Drug Regulatory Affairs, K. G. R. L College of Pharmacy, Bhimavaram-534201, A.P, India

A B S T R A C T
The application of quality by design (QbD) in pharmaceutical product development is now a thrust area for the regulatory authorities and the pharmaceutical industry. International Conference on Harmonization and United States Food and Drug Administration (USFDA) emphasized the principles and applications of QbD in pharmaceutical development in their guidance for the industry. QbD attributes are addressed in question-based review, developed by USFDA for chemistry, manufacturing, and controls section of abbreviated new drug applications. QbD principles, when implemented, lead to a successful product development, subsequent prompt regulatory approval, reduce exhaustive validation burden, and significantly reduce post-approval changes. The key elements of QbD viz., target product quality profile, critical quality attributes, risk assessments, design space, control strategy, product lifecycle management, and continual improvement are discussed to understand the performance of dosage forms within design space. Design of experiments, risk assessment tools, and process analytical technology are also discussed for their role in QbD. This review underlines the importance of QbD in inculcating science-based approach in pharmaceutical product development.
Keywords: USFDA, risk assessments, QbD